Panel for This Discussion
Jo Ellen Slurzberg will Moderate this Forum. She has developed and implemented complex reimbursement strategies for a spectrum of innovative biomedical, pharmaceutical and medical device technologies in the U.S. and abroad.
Jeff Levin-Scherz, MD, MBA, Assistant Professor Health Policy and Management at Harvard T.H.Chan School of Public Health, will present a broad overview of the factors that are driving the disconnect between spending and outcomes in US healthcare and explore some critical healthcare cost myths and provide some prescriptions for how to overcome them.
James Wallace, MBA, President, AmeriPlus Selectexecutive about leading cost drivers he feels are ripe for innovation from the med tech industry. He’ll also explore some promising innovations that insurers were receptive to as well as some attempts at innovation when they weren’t so receptive.
Wendy Zhong, PhD Principal Health Economist at Boston Scientific (Watchman) will talk about what goes into developing a compressive health economic argument for payers, facilities, and patients. She’ll then talk a little about what she and her team are doing on Boston Scientific’s Watchman product.The US spends more than any other country in the developed world on healthcare on both a per capita (US$ PPP) and percentage of GDP basis. Despite that high spending and incredible technical sophistication, US healthcare ranks near the bottom of the developed world on many health care quality indicators such as life expectancy and infant mortality.
Who Should Attend:
- Physicians, Hospital, and Insurance Groups
- Innovative Scientists, Engineers,Physicians, and Economists
- Med-tech entrepreneurs, executives, and product managers